TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 17277998
Drug: Clopidogrel (75
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clopidogrel (75 mg daily for at least 3 days)
Study: 11809123
Drug: nabumetone (1000
Approvals — FDA: no, EMA: no, PMDA: no
Description: nabumetone (1000 mg/day)
Study: 11809123
Drug: diclofenac sodium
Normalized name: Diclofenac Sodium
DrugBank: Diclofenac (DB00586)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: diclofenac sodium (75 mg/day)
Study: 3043571
Drug: 40 ml
Normalized name: hydrogen peroxide 40 ML/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 ml prilocaine 1.5%
Study: 3043571
Drug: 40 ml
Normalized name: hydrogen peroxide 40 ML/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 ml bupivacaine 0.375%
Study: 3043571
Drug: 20 ml
Normalized name: Exact-Med, 20 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 ml prilocaine 1% + 20 ml bupivacaine 0.5%
Study: 3043571
Drug: 20 ml
Normalized name: Exact-Med, 20 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 ml prilocaine 2% + 20 ml bupivacaine 0.5%
Study: 3043571
Drug: 20 ml
Normalized name: Exact-Med, 20 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 ml prilocaine 2% + 20 ml bupivacaine 0.375%
Study: 29033547
Drug: Tablet formulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablet formulation of tacrolimus
Study: 8888665
Drug: Vitamin E
Normalized name: Vitamin E
DrugBank: Vitamin E (DB00163)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Vitamin E 400 IU daily
Study: 17152732
Drug: Mildronate 500
Normalized name: tiludronate
DrugBank: Tiludronic acid (DB01133)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Mildronate 500 mg/day
Study: 17152732
Drug: Traditional basal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Traditional basal therapy
Study: 14747052
Drug: Second-line hormonal
Normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Second-line hormonal therapy using ketoconazole and hydrocortisone
Study: 14747052
Drug: Docetaxel and
Normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Docetaxel and estramustine combination chemotherapy
Study: 9351755
Drug: Vaginal misoprostol
Normalized name: Misoprostol
DrugBank: Misoprostol (DB00929)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Vaginal misoprostol 200 microg every 3 hours for a maximum of five doses in the first 24 hours
Study: 9351755
Drug: Oral misoprostol
Normalized name: Misoprostol
DrugBank: Misoprostol (DB00929)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral misoprostol 200 microg every 3 hours for a maximum of five doses in the first 24 hours
Study: 31994364
Drug: 10 mL/kg/h
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mL/kg/h rate 5% Dextrose infusion preoperatively for 30 minutes, followed by Ringer's lactate until the end of surgery
Study: 31994364
Drug: 10 mL/kg/h
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mL/kg/h rate of Ringer's lactate preoperatively for 30 minutes, followed by 5% Dextrose during the operation
Study: 31994364
Drug: Ringer's lactate
Normalized name: Ringer's lactate/gel dressing 2.2" TOPICAL KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ringer's lactate solution infusion at a rate of 10 mL/kg/h preoperatively and intraoperatively
Study: 27004290
Drug: Platelet-rich plasma
Normalized name: PLATELET-RICH PLASMA, AUTOLOGOUS
DrugBank: Platelet Rich Plasma (DB19295)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Platelet-rich plasma (PRP) gel plus bovine-derived xenograft
Study: 27004290
Drug: Bovine-derived xenograft
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bovine-derived xenograft without PRP gel
Study: 17996409
Drug: Immediate release
Normalized name: Namenda, immediate release oral kit
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immediate release formulation of metformin hydrochloride
Study: 17996409
Drug: Extended release
Normalized name: Tylenol Extended Release
Approvals — FDA: no, EMA: no, PMDA: no
Description: Extended release formulation of metformin hydrochloride
Study: 15714177
Drug: Calcium (400
Normalized name: calcium carbonate 160 mg calcium (400 mg) ORAL TABLET,CHEWABLE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcium (400 mg daily)
Study: 15714177
Drug: Calcium (400
Normalized name: calcium carbonate 160 mg calcium (400 mg) ORAL TABLET,CHEWABLE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcium (400 mg daily) + Vitamin D3 (25,000 IU monthly)
Study: 12890859
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (usual care: NSAIDs, muscle relaxants, paracetamol, back exercises)
Study: 8429117
Drug: Ranitidine 300
Normalized name: ranitidine 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ranitidine 300 mg bid
Study: 4059297
Drug: triletide (1.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: triletide (1.5 g/day)
Study: 4059297
Drug: antacids (0.8
Approvals — FDA: no, EMA: no, PMDA: no
Description: antacids (0.8 g/day each of aluminium hydroxide and magnesium hydroxide)
Study: 4059297
Drug: triletide (1.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: triletide (1.5 g/day) in combination with antacids
Study: 30824206
Drug: Photobiomodulation treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Photobiomodulation treatment
Study: 28718728
Drug: Clofarabine (CIA)
Normalized name: Clofarabine
DrugBank: Clofarabine (DB00631)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Clofarabine (CIA) 15 mg/m2
Study: 27112311
Drug: Microenema with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Microenema with phenobarbital tablets crushed and suspended in 20 mL of tap water (MC-20)
Study: 27112311
Drug: Microenema with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Microenema with phenobarbital tablets crushed and suspended in 6 mL of tap water (MC-6)
Study: 21805307
Drug: Prebiotic (mannanoligosaccharide)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prebiotic (mannanoligosaccharide) 4 g/calf/day
Study: 20080837
Drug: Diiodothyropropionic acid
Normalized name: 3,5-diiodothyropropionic acid
DrugBank: 3,5-diiodothyropropionic acid (DB12629)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diiodothyropropionic acid (DITPA) at escalating doses (90 to 180, 270, and 360 mg/d)
Study: 27225602
Drug: Treadmill exercise
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Treadmill exercise program (walking on a treadmill with fixed 0% grade, 3 times weekly for 48 weeks, first 12 weeks supervised, remaining 36 weeks unsupervised)
Study: 27225602
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (encouraged to walk twice a week for 45 minutes and received standard health recommendations)
Study: 19756774
Drug: Aprepitant (125
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aprepitant (125 mg PO, ondansetron 32 mg IV, dexamethasone 12 mg day 1; aprepitant 80 mg days 2-3; dexamethasone 8 mg qd days 2-4)
Study: 19756774
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (ondansetron 32 mg IV, dexamethasone 20 mg PO day 1; dexamethasone 8 mg bid days 2-4)
Study: 12631089
Drug: 1 g
Normalized name: Molds 1 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 g vitamin C
Study: 12631089
Drug: 1 g
Normalized name: Molds 1 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 g vitamin C (healthy subjects)
Study: 10973867
Drug: Oral salbutamol
Normalized name: salbutamol
DrugBank: Albuterol (DB01001)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral salbutamol (five doses of 4 mg)
Study: 10973867
Drug: Inhaled salbutamol
Normalized name: salbutamol
DrugBank: Albuterol (DB01001)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Inhaled salbutamol (two doses of 100 microgram)
Study: 10973867
Drug: Maximum dosage
Normalized name: Maximum-H
DrugBank: Hydrocortisone (DB00741)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Maximum dosage of inhaled salbutamol (1600 microgram in 24 h, 800 microgram in the last 4 h)
Study: 8836892
Drug: Lymphoblastoid IFN
Normalized name: IFNγ
DrugBank: Interferon Gamma (DB15753)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lymphoblastoid IFN alpha 3 or 5 MU three times a week for 6 or 12 months (total dosage 216‐720 MU)
Study: 1592888
Drug: Metyrapone (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metyrapone (30 mg/kg body weight) administered at midnight
Study: 19489488
Drug: Western medicine
Normalized name: Medicaine Sting
Approvals — FDA: no, EMA: no, PMDA: no
Description: Western medicine Nicardipine
Study: 18681090
Drug: Indacaterol 400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Indacaterol 400 microg via single-dose dry powder inhaler (SDDPI)
Study: 14506028
Drug: High-dose azithromycin
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose azithromycin (20 mg/kg once a day for 3 days)
Study: 14506028
Drug: High-dose amoxicillin-clavulanate
Normalized name: amoxicillin / clavulanate
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose amoxicillin-clavulanate (90 mg/kg divided twice a day for 10 days)
Study: 14506028
Drug: High-dose azithromycin
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose azithromycin
Study: 14506028
Drug: High-dose amoxicillin-clavulanate
Normalized name: amoxicillin / clavulanate
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose amoxicillin-clavulanate
Study: 8678516
Drug: Leucovorin (LV,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Leucovorin (LV, 30 mg/body) + 5‐fluorouracil (5‐FU 500 ‐ 750 mg/body) administered intravenously
Study: 8678516
Drug: Leucovorin (LV,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Leucovorin (LV, 30 mg/body) + 5‐fluorouracil (5‐FU 500 ‐ 750 mg/body) administered via intra‐hepatic artery injection
Study: 31880795
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of GRS and family history (FH)
Study: 25799001
Drug: WhatsApp chat
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: WhatsApp chat room-based competition for oral hygiene compliance
Study: 25799001
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (standard oral hygiene instructions without app)
Study: 19279226
Drug: Methylprednisolone plus
Normalized name: Methylprednisolone
DrugBank: Methylprednisolone (DB00959)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Methylprednisolone plus lidocaine (steroid)
Study: 17559628
Drug: Experimental gingivitis
Approvals — FDA: no, EMA: no, PMDA: no
Description: Experimental gingivitis (initial prophylaxis followed by total neglect of oral hygiene)
Study: 17559628
Drug: Persistent gingivitis
Normalized name: BD Persist
DrugBank: Povidone-iodine (DB06812)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Persistent gingivitis (continued habitual insufficient oral hygiene)
Study: 15159285
Drug: Prednisolone 20
Normalized name: prednisolone 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prednisolone 20 mg/day for three months, with tapering dose in month 4, plus multidrug treatment
Study: 15159285
Drug: Multidrug treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multidrug treatment alone
Study: 28707987
Drug: Caffeine treatment
Normalized name: Caffeine
DrugBank: Caffeine (DB00201)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Caffeine treatment
Study: 28249684
Drug: LMA with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: LMA with subparalytic dose of MR (group 3)
Study: 25403334
Drug: Rhodiola crenulata
Normalized name: RHODIOLA CRENULATA ROOT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rhodiola crenulata 500 mg daily for 12 weeks
Study: 25403334
Drug: Placebo (starch/phosphate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (starch/phosphate buffered saline) daily for 12 weeks
Study: 18081753
Drug: Dapsone +
Normalized name: Dapsone
DrugBank: Dapsone (DB00250)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Dapsone + desloratadine (10 mg daily)
Study: 18081753
Drug: Desloratadine (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Desloratadine (10 mg daily)
Study: 1862893
Drug: bupivacaine 0.5%
Normalized name: BUPivacaine 0.5% injectable kit
Approvals — FDA: no, EMA: no, PMDA: no
Description: bupivacaine 0.5% 8 ml initial dose with fentanyl 0.0002%
Study: 6641089
Drug: Low-dose perhexiline
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose perhexiline during exercise training
Study: 6641089
Drug: Low-dose perhexiline
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose perhexiline
Study: 28914700
Drug: 30 mg
Normalized name: agar 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 mg of IV ketorolac
Study: 28185214
Drug: Lipoprotein apheresis
Normalized name: Zaire ebolavirus envelope glycoprotein Injection [Ervebo]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lipoprotein apheresis (LA), regular LA treatment over 5 years
Study: 20853269
Drug: 1.25 mg
Normalized name: menthol 1.25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.25 mg intravitreal bevacizumab at the end of surgery
Study: 16368284
Drug: Oral anticoagulants
Normalized name: CPDA-1 Anticoagulant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral anticoagulants (OAC) plus antiplatelet therapy
Study: 9092958
Drug: Topiramate (TPM)
Normalized name: Topiramate
DrugBank: Topiramate (DB00273)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Topiramate (TPM) at target daily dosages of up to 9 mg/kg/day
Study: 9092958
Drug: Adjunctive TPM
Normalized name: TPM
DrugBank: Topiramate (DB00273)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Adjunctive TPM therapy
Study: 9092958
Drug: TPM monotherapy
Normalized name: TPM
DrugBank: Topiramate (DB00273)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: TPM monotherapy substitution
Study: 8403580
Drug: Hyaluronic acid
Normalized name: hyaluronic acid
DrugBank: Hyaluronic acid (non-animal stabilized) (DB19175)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hyaluronic acid (HA), 7 injections over 6 weeks
Study: 8403580
Drug: Mucopolysaccharide polysulfuric
Normalized name: sulfated mucopolysaccharides
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mucopolysaccharide polysulfuric acid ester (MPA), 13 injections over 6 weeks
Study: 29975728
Drug: Protein-reduced infant
Normalized name: protein C
DrugBank: Protein C (DB11312)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Protein-reduced infant formula (1.89 g protein/100 kcal) with alpha-lactalbumin enriched whey and long-chain polyunsaturated fatty acids (LC-PUFA)
Study: 29975728
Drug: Standard formula
Normalized name: Standard formula
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard formula (2.2 g protein/100 kcal) without LC-PUFA
Study: 24615094
Drug: Remifentanil (target
Approvals — FDA: no, EMA: no, PMDA: no
Description: Remifentanil (target plasma concentration 3 ng/mL)
Study: 24615094
Drug: Propofol (target
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propofol (target plasma concentration 2 μg/mL)
Study: 18398095
Drug: High-dose ICE
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose ICE chemotherapy (ifosfamide, carboplatin, etoposide) with PBPC support
Study: 18398095
Drug: Standard-dose ICE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard-dose ICE chemotherapy (ifosfamide, carboplatin, etoposide)
Study: 18398095
Drug: High-dose ICE
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose ICE chemotherapy
Study: 18398095
Drug: Standard-dose ICE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard-dose ICE chemotherapy
Study: 15068496
Drug: simvastatin 40
Normalized name: simvastatin 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: simvastatin 40 mg/day
Study: 16872244
Drug: ezetimibe 10
Normalized name: ezetimibe 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: ezetimibe 10 mg/day plus simvastatin 40 mg/day
Study: 14635608
Drug: Diuretics (in
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diuretics (in males)
Study: 14635608
Drug: Antihypertensive treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antihypertensive treatment (phase 1)
Study: 8615470
Drug: Preoperative combination
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Preoperative combination treatment (radiation, intraluminal hyperthermia, and 5-fluorouracil suppositories)
Study: 8615470
Drug: Surgery after
Approvals — FDA: no, EMA: no, PMDA: no
Description: Surgery after preoperative combination treatment
Study: 3805328
Drug: Lithium treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lithium treatment (0.8 mEq/liter for 1 week)
Study: 29971998
Drug: Auricular point
Normalized name: ActivOn Joint & Muscle
Approvals — FDA: no, EMA: no, PMDA: no
Description: Auricular point sticking therapy at bilateral shenmen (TF4), pizhixia (AT4), jiaogan (AH6a) and gangmen (HX5), pressing 3-6 times every day, once 3-5 min.
Study: 29971998
Drug: Combined group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined group (EA + auricular point sticking therapy).
Study: 25339836
Drug: Split-dose of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Split-dose of 2-litre PEG-ELS
Study: 25339836
Drug: Whole-dose of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Whole-dose of 2-litre PEG-ELS
Study: 12140209
Drug: Hypotonic (150
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hypotonic (150 mOsm/l) 0.4% hyaluronate eye drops
Study: 9656236
Drug: IL‐2, LAK
Approvals — FDA: no, EMA: no, PMDA: no
Description: IL‐2, LAK adoptive immunotherapy
Study: 7654922
Drug: Self-medication
Approvals — FDA: no, EMA: no, PMDA: no
Description: Self-medication
Study: 7654922
Drug: Self-medication with
Normalized name: chloroxylenol Medicated Pad [E-Z Scrub with Ultradex]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Self-medication with antibiotics
Study: 7654922
Drug: Self-medication with
Normalized name: chloroxylenol Medicated Pad [E-Z Scrub with Ultradex]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Self-medication with vitamins
Study: 7654922
Drug: Self-medication for
Approvals — FDA: no, EMA: no, PMDA: no
Description: Self-medication for asthenia
Study: 7654922
Drug: Previous medical
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Previous medical prescription
Study: 2647677
Drug: Any preparatory
Normalized name: cranberry preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Any preparatory treatment
Study: 12138261
Drug: Steroid pulse
Normalized name: dulse extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Steroid pulse therapy (steroid pulse group)
Study: 31424972
Drug: Tailored DAA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tailored DAA treatment based on baseline resistance findings, including prolonged treatment duration of NS5A-inhibitor and sofosbuvir (SOF) and/or addition of ribavirin (RBV) for patients with baseline Y93H.
Study: 31424972
Drug: Standard DAA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard DAA treatment for patients without baseline Y93H and all patients in the control group.
Study: 31424972
Drug: Personalized treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Personalized treatment for patients with baseline Y93H in the intervention group.
Study: 31424972
Drug: Standard treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard treatment for patients with baseline Y93H in the control group.
Study: 15731561
Drug: Progestin therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Progestin therapy
Study: 9793946
Drug: Retrobulbar anesthesia
Normalized name: Gelato Anesthetic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Retrobulbar anesthesia (4 cc of a 50:50 mixture of 2% xylocaine and 0.75% bupivacaine with 150 units of hyaluronidase)
Study: 9793946
Drug: Peribulbar anesthesia
Normalized name: Gelato Anesthetic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Peribulbar anesthesia (6 cc of a 50:50 mixture of 2% xylocaine and 0.75% bupivacaine with 150 units of hyaluronidase)
Study: 2565416
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg bd tazifylline
Study: 1052162
Drug: Pentoxifylline (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pentoxifylline (200 mg intravenous infusion)
Study: 27376907
Drug: Saline solution
Normalized name: Unisol 4 Saline Solution
DrugBank: Sodium chloride (DB09153)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Saline solution (10 ml)
Study: 31669091
Drug: 1% iodine
Normalized name: 1% Iodine Tincture
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1% iodine solution (group A)
Study: 31669091
Drug: 2% iodine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2% iodine solution (group B)
Study: 28481882
Drug: 800 IU
Normalized name: Vitamin E 800 IU Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: 800 IU vitamin D3 daily for 6 months (Supplementation Study)
Study: 28481882
Drug: 300 IU
Normalized name: Follistim AQ 300 IU per 0.36 ML Cartridge
Approvals — FDA: no, EMA: no, PMDA: no
Description: 300 IU vitamin D3 daily in fortified milk for 7 weeks (Fortification Study)
Study: 25297721
Drug: Topical clobetasol
Normalized name: clobetasol Topical Foam
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical clobetasol propionate cream (0.05%) applied at home
Study: 25297721
Drug: Topical silver
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical silver nitrate (99%) in the outpatient clinic
Study: 21771340
Drug: No-treatment control
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: No-treatment control group.
Study: 16338019
Drug: Amantadine 100
Normalized name: amantadine 100 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amantadine 100 mg twice daily for 48 weeks
Study: 14984391
Drug: Integrated treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Integrated treatment with cognitive‐behaviour therapy and coping training
Study: 8434556
Drug: Probucol 0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Probucol 0.5 g twice daily
Study: 27650295
Drug: Palonosetron plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Palonosetron plus TIVA (palonosetron 0.075 mg i.v.)
Study: 27650295
Drug: TIVA (normal
Approvals — FDA: no, EMA: no, PMDA: no
Description: TIVA (normal saline 1.5 ml i.v.)
Study: 28560383
Drug: 30 mg
Normalized name: agar 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 mg genistein daily for 3-6 weeks
Study: 10595786
Drug: Lutein (15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lutein (15 mg/day)
Study: 8951132
Drug: Intracervical prostaglandin
Normalized name: Prostaglandin D2
DrugBank: Prostaglandin D2 (DB02056)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intracervical prostaglandin E2 (PGE2) gel (0.5 mg) followed by insertion of a 24-Foley catheter